LS132.8G2 [8G2] (ATCC® HB-12550)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  /  Disease: Lymphoma

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease Lymphoma
Strain

Strain:  C57BL/6  (B cell); BALB/c  (myeloma)

Applications
The antibody binds to the human CC-chemokine receptor 2 (CCR2).
Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region.
Storage Conditions liquid nitrogen vapor phase
Images
Derivation
Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region. Spleen cells were fused Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 2 (CCR2).
Comments
Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region. Spleen cells were fused Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 2 (CCR2).
Complete Growth Medium Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose and supplemented with 25 mM HEPES, 20 pg/ml mouse recombinant Interleukin-6 (IL-6) and 20% fetal bovine serum
Subculturing
Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation and subsequent resuspension at 1 x 10(5) viable cells/ml.
Interval: Maintain cell concentration between 1.0 x 10(5) and 1.0 x 10(6) cells/ml.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype IgM kappa
Name of Depositor LeukoSite, Inc.
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
References

LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,312,689 dated Nov 6 2001

LaRosa GJ, et al. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,352,832 dated Mar 5 2002

LaRosa GJ. Method of inhibiting leukocyte trafficking by anti-CCR2 amino-terminal domain antibodies. US Patent 6,395,497 dated May 28 2002

LaRosa GJ. Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies. US Patent 6,406,865 dated Jun 18 2002

LaRosa GJ. Anti-CCR2 antibodies. US Patent 6,406,694 dated Jun 18 2002

LaRosa GJ. Method of inhibiting cell function associated with CCR2 by anti-CCR2 amino-terminal domain antibodies. US Patent 6,448,021 dated Sep 10 2002

LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,451,522 dated Sep 17 2002

. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,458,353 dated Oct 1 2002

LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,491,915 dated Dec 10 2002

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,312,689 dated Nov 6 2001

LaRosa GJ, et al. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,352,832 dated Mar 5 2002

LaRosa GJ. Method of inhibiting leukocyte trafficking by anti-CCR2 amino-terminal domain antibodies. US Patent 6,395,497 dated May 28 2002

LaRosa GJ. Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies. US Patent 6,406,865 dated Jun 18 2002

LaRosa GJ. Anti-CCR2 antibodies. US Patent 6,406,694 dated Jun 18 2002

LaRosa GJ. Method of inhibiting cell function associated with CCR2 by anti-CCR2 amino-terminal domain antibodies. US Patent 6,448,021 dated Sep 10 2002

LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,451,522 dated Sep 17 2002

. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,458,353 dated Oct 1 2002

LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,491,915 dated Dec 10 2002